All In Biotech

Drug Trial Radar · NCT03105375

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of X842 in Human: A Single/Multiple Ascending Dose Study

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of X842 in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

39

Actual

Start

Feb 21, 2017

Primary completion

Oct 12, 2017

Study completion Oct 12, 2017

Sponsor

Lead sponsor
Cinclus Pharma Holding ABIndustry
Sponsor type
Industry
First posted
Apr 7, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess and analyze the safety, tolerability and PK/PD data following single ascending and multiple ascending doses of X842 in healthy subjects.

Conditions

  • Healthy Volunteers

Interventions

  • Single ascending dose of X842Drug

    Each subject in a the same cohort will be assigned to the same single dose of X842. The subjects in the subsequent cohort will be assigned to a single dose of X842 based on safety and efficacy data generated from the previous cohort.

  • Multiple ascending dose of X842Drug

    Each subject in a the same cohort will be assigned to the same dose of X842 once daily for five days. The subjects in the subsequent cohort will be assigned to same dose of X842 once daily for five days based on safety and efficacy data generated from the previous cohort.

  • LosecDrug

    Each subject in one cohort will be assigned to a standard dose of omeprazole once daily for five days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence and frequency of AEs, changes in laboratory parameters, vital signs and physical examination after single and multiple doses of X842. Summary statistics will be applied.Time frame: Five weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinical Trial Consultants

    Uppsala, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.